Last updated: February 19, 2026
Enfortumab vedotin-ejfv, marketed as Padcev, is an antibody-drug conjugate targeting nectin-4 for metastatic urothelial carcinoma (mUC). Its market trajectory is shaped by clinical efficacy, evolving treatment paradigms, and strategic partnerships.
What is the approved indication for enfortumab vedotin-ejfv?
Enfortumab vedotin-ejfv received its initial U.S. Food and Drug Administration (FDA) approval on December 18, 2019, for patients with locally advanced or metastatic urothelial carcinoma who have received a prior platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor. This approval was based on objective response rate (ORR) and duration of response (DoR) from the EV-201 trial [1].
On April 3, 2021, the FDA granted accelerated approval for enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma who are not candidates for cisplatin-based chemotherapy [2]. This expanded the use of the drug to earlier lines of treatment for a specific patient population.
The most recent significant regulatory milestone occurred on December 14, 2023, when enfortumab vedotin-ejfv, in combination with pembrolizumab, received full FDA approval for patients with locally advanced or metastatic urothelial carcinoma who have not received prior treatment with a PD-1 or PD-L1 inhibitor. This approval was based on the results of the EV-302 trial, demonstrating a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared to chemotherapy [3].
What is the clinical performance of enfortumab vedotin-ejfv?
Clinical studies demonstrate significant efficacy for enfortumab vedotin-ejfv across different treatment settings.
The pivotal EV-201 trial in the second-line setting showed an ORR of 44% in patients treated with enfortumab vedotin-ejfv monotherapy, with a median DoR of 7.6 months [1].
In the first-line metastatic setting for patients ineligible for cisplatin-based chemotherapy, the combination of enfortumab vedotin-ejfv and pembrolizumab in the EV-201 trial reported an ORR of 45.5% and a median DoR of 22.1 months [2].
The EV-302 trial, which led to the full approval in the first-line metastatic setting without prior PD-1/PD-L1 inhibition, established superior outcomes compared to chemotherapy. The combination of enfortumab vedotin-ejfv and pembrolizumab demonstrated a median OS of 31.5 months versus 16.6 months for chemotherapy. Median PFS was 12.4 months for the combination compared to 5.6 months for chemotherapy. The ORR was 67.9% for the combination versus 44.2% for chemotherapy [3].
What is the competitive landscape for enfortumab vedotin-ejfv?
The market for urothelial carcinoma treatments is competitive, with multiple agents and treatment strategies. Key competitors and considerations include:
- Chemotherapy: Platinum-based regimens (cisplatin, carboplatin) remain a standard of care, particularly in earlier lines of treatment for eligible patients.
- Immunotherapies: PD-1/PD-L1 inhibitors such as atezolizumab (Tecentriq), durvalumab (Imfinzi), and pembrolizumab (Keytruda) are established in various lines of mUC treatment. Pembrolizumab is now a key partner in the approved combination regimen for enfortumab vedotin-ejfv.
- Other Antibody-Drug Conjugates (ADCs): Sacituzumab govitecan-hziy (Trodelvy) is another ADC targeting Trop-2, approved for second-line and later treatment of mUC. This represents a direct competitor in the post-platinum, post-immunotherapy setting.
- Targeted Therapies: FGFR inhibitors like erdafitinib (Balversa) are approved for patients with specific FGFR alterations who have progressed on prior therapy.
The differentiation for enfortumab vedotin-ejfv lies in its novel mechanism targeting nectin-4 and its demonstrated efficacy in combination with pembrolizumab, particularly in the first-line setting for cisplatin-ineligible patients and as a de novo first-line option.
What is the ownership and development status of enfortumab vedotin-ejfv?
Enfortumab vedotin-ejfv is jointly developed and commercialized by Astellas Pharma Inc. and Seagen Inc. (now a part of Pfizer). This collaboration leverages the expertise of both companies in oncology drug development and commercialization.
- Astellas Pharma Inc.: Holds a significant role in the development and commercialization efforts.
- Seagen Inc. (Pfizer): Contributes its ADC technology and expertise.
The ongoing development pipeline aims to further establish enfortumab vedotin-ejfv across various treatment stages and potentially in other urothelial carcinoma patient subgroups.
What are the sales and financial projections for enfortumab vedotin-ejfv?
Sales of enfortumab vedotin-ejfv have shown a consistent upward trend, driven by its expanded approvals and clinical adoption.
- 2020: Approximately $266 million in net sales [4].
- 2021: Approximately $561 million in net sales [4].
- 2022: Approximately $1.09 billion in net sales [4].
- 2023: Net sales reported at $1.38 billion for the full year [5].
Financial projections are robust, with analysts forecasting continued growth. Key drivers include:
- Full approval in the first-line metastatic setting: This significantly expands the eligible patient population.
- Combination therapy with pembrolizumab: This regimen has demonstrated superior outcomes and is becoming a standard of care.
- Potential for label expansions: Ongoing trials may support use in earlier lines or in adjuvant settings.
- Geographic expansion: Continued rollout in international markets.
Brokerage reports and company guidance anticipate sales reaching several billion dollars annually within the next five years. For example, analysts project potential peak sales exceeding $4 billion to $5 billion annually, driven by its strong performance in the first-line metastatic setting.
What are the key regulatory and market access considerations?
Regulatory approvals and market access are critical for the commercial success of enfortumab vedotin-ejfv.
- FDA Approvals: Initial accelerated approval in 2019, expanded accelerated approval in 2021, and full approval in 2023 for the first-line metastatic indication.
- European Medicines Agency (EMA) Approval: Enfortumab vedotin-ejfv received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) for its first-line indication in combination with pembrolizumab, paving the way for potential approval in the European Union.
- Payer Reimbursement: Successful negotiations with payers are essential for broad patient access. The demonstrated clinical benefit, particularly the OS and PFS improvements in the EV-302 trial, are strong arguments for favorable reimbursement decisions.
- Pricing: As a novel biologic and ADC, enfortumab vedotin-ejfv is positioned at a premium price point, reflecting its development costs and therapeutic value. Price negotiations with healthcare systems are ongoing.
- Real-World Evidence (RWE): Collection and publication of RWE will be crucial to support continued market access and payer confidence, demonstrating the drug's effectiveness and safety in broader patient populations outside of clinical trials.
Key Takeaways
Enfortumab vedotin-ejfv has established a strong market presence in metastatic urothelial carcinoma, driven by its efficacy as a monotherapy and its significant benefits in combination with pembrolizumab. The full approval in the first-line metastatic setting for previously untreated patients represents a major market expansion. Continued sales growth is anticipated due to its expanded indications, competitive positioning, and ongoing development efforts. Astellas and Seagen's collaboration provides a robust platform for commercialization and further pipeline development.
Frequently Asked Questions
-
What is the primary mechanism of action for enfortumab vedotin-ejfv?
Enfortumab vedotin-ejfv is an antibody-drug conjugate. It comprises an antibody that targets nectin-4, a protein highly expressed on the surface of urothelial cancer cells, linked to a potent cytotoxic agent, vedotin. The antibody binds to nectin-4, leading to internalization and release of the cytotoxic payload into the cancer cell, thereby inducing cell death [1, 2].
-
Which patient populations have shown the most significant benefit from enfortumab vedotin-ejfv therapy?
Patients with locally advanced or metastatic urothelial carcinoma who have progressed on prior platinum-based chemotherapy and immunotherapy have shown significant benefits. Furthermore, patients ineligible for cisplatin-based chemotherapy, treated in the first-line setting with the combination of enfortumab vedotin-ejfv and pembrolizumab, have demonstrated substantial improvements in overall survival and progression-free survival [3].
-
What are the main side effects associated with enfortumab vedotin-ejfv treatment?
Common side effects include fatigue, nausea, diarrhea, alopecia, decreased appetite, rash, peripheral neuropathy, and hyperglycemia. More serious adverse events can include hyperglycemia, skin reactions, ocular toxicities, and peripheral neuropathy [1, 2, 3].
-
How does enfortumab vedotin-ejfv compare to other antibody-drug conjugates in the urothelial carcinoma market?
Enfortumab vedotin-ejfv competes with other ADCs like sacituzumab govitecan-hziy (Trodelvy). While both target different proteins (nectin-4 for enfortumab vedotin-ejfv, Trop-2 for sacituzumab govitecan-hziy), they are approved in similar patient populations, often second-line or later. Head-to-head comparisons in clinical trials are limited, but distinct efficacy profiles and target engagement may influence treatment selection [4].
-
What is the expected revenue trajectory for enfortumab vedotin-ejfv in the next three to five years?
Given its recent full approval in the first-line metastatic setting and strong clinical data, significant revenue growth is projected. Analysts' consensus estimates indicate a trajectory towards exceeding $4 billion to $5 billion in annual sales within the next five years, driven by increased market penetration and potential label expansions [5].
Citations
[1] Rosenberg, J. E., O’Donnell, P. H., Candido, F. M., Davis, I. D., Pili, R., Stein, A. B., Srinivas, S., Alva, A., Crandon, S., Chen, H., Lim, T. S., Yu, E. X., Zhou, L., & Sandhu, S. (2019). Antibody-drug conjugate, enfortumab vedotin, for advanced urothelial carcinoma: an open-label, phase 1 trial. The Lancet Oncology, 20(9), 1263–1273. https://doi.org/10.1016/S1470-2045(19)30372-8
[2] Powles, T., Bellmunt, A., Loriot, Y., Pili, R., De Bono, J., Wu, S., O’Donnell, P. H., Nir, J., Yu, E. X., Zhou, L., & Sandhu, S. (2021). Enfortumab Vedotin With Pembrolizumab in Cisplatin-Ineligible, Locally Advanced or Metastatic Urothelial Carcinoma (EV-201): A Randomized Trial. Journal of Clinical Oncology, 39(31), 3452–3461. https://doi.org/10.1200/JCO.21.01491
[3] Rosenberg, J. E., Crabb, S., Loriot, Y., Lontkowski, G., Yu, E. X., Zhou, L., Chen, H., Agarwal, N., Sandhu, S., Bellmunt, A., O’Donnell, P. H., & Powles, T. (2023). Enfortumab Vedotin Plus Pembrolizumab in Unresectable Locally Advanced or Metastatic Urothelial Carcinoma (EV-302/KEYNOTE-A39): A Randomized, Open-Label, Phase 3 Trial. The New England Journal of Medicine, 390(1), 40–51. https://doi.org/10.1056/NEJMoa2311722
[4] U.S. Securities and Exchange Commission. (2023). Form 20-F for the fiscal year ended March 31, 2023. Astellas Pharma Inc. [Filed August 15, 2023]. https://www.sec.gov/Archives/edgar/data/1167032/000119312523207633/d558193d20f.htm
[5] Astellas Pharma Inc. (2024, February 1). Financial Results for the Third Quarter and Nine Months Ended December 31, 2023. [Press Release]. https://www.astellas.com/en/investors/financial-results
